Le Lézard
Classified in: Health, Science and technology
Subjects: PDT, TRI, FDA

FDA Clearance Awarded to Tyber Medical for NiTy+ One-Shot Staple Fixation System


Innovative Bone Fixation System Offers Surgeons a Single-Step Staple Implantation Process

BETHLEHEM, Pa., Nov. 15, 2022 /PRNewswire/ -- Tyber Medical LLC, the global, leading private-label medical device provider for major orthopedic trauma, extremity, and spine companies, has been awarded a U.S. Food and Drug Administration (FDA) 510(k) clearance for its new NiTy+ One-Shottm Staple Fixation System. The NiTy+ One-Shot is the first instrument of its kind in the bone-fixation device market to feature a uniquely designed, single-pass insertion instrument. Designed with surgical efficiency in mind, the NiTy+ One-Shot is particularly beneficial in the case of fracture, osteotomy fixation, and joint arthrodesis.

Surgeons can deploy and insert staples with one instrument, while remaining focused on the field of view at all times.

"We are pleased to receive another FDA clearance that extends our reach into the orthopedic device market with our ever-growing suite of cleared bone-fixation devices," said Tyber Medical CEO and President Jeff Tyber. "Our product design and engineering team developed a superior method for staple implantation that enhances surgical efficiency. With one instrument, surgeons can deploy and insert staples, while remaining focused on the field of view at all times."

The system's innovative insertion tool is equipped with pre-loaded staples and an integrated tamping mechanism, eliminating the need for a second instrument to fully seat staples into the bone requiring fixation. Two instruments are combined into a single insertion tool, which can also reattach to the staple, allowing enhanced positioning control.

According to Tyber Medical's Senior Project Engineer Abe Perryman, physicians have responded favorably to the company's new staple system. "The feedback we have received from surgeons involved in the cadaveric trials has been overwhelmingly positive. What they appreciate most is how our innovative insertion tool allows for streamlined bone staple implantation in orthopedic extremities surgery," Perryman said.

Tyber Medical's NiTy+ One-Shot Staple Fixation System consists of sterile, single-use orthopedic implants and fully disposable instruments, removing the need for facility reprocessing. The compression staples are constructed from super-elastic nickel-titanium (Nitinol) and are available in two or four-legged designs with multiple combinations of bridge widths, leg lengths, and cross sections to accommodate various anatomies and pathologies. The staple implant applies optimum compression across bone segments when the staple implant legs are released. The disposable inserter supplies opposing forces to the staple legs to keep them parallel during implantation.

About Tyber Medical LLC

Tyber Medical is committed to providing rapid access to FDA-cleared and CE-marked private label, orthopedic device technology that advance patient care and healing outcomes. Since its founding in 2012, Tyber Medical LLC has released more than fifty extremity/trauma/spine systems, quickly becoming a leading orthopedic device provider. The company's medical device portfolio effectively offers its partners a quick and seamless path to market, by filling product offering gaps in as little as four months through vertically integrated design, engineering, manufacturing, quality management, regulatory, clinical research, and MDR compliance. Tyber Medical is committed to developing and utilizing differentiated, bioengineered technologies, including unique surface treatments and coatings, to make advanced orthopedic implants.

Contact: Eric Dickson, Tyber Medical
Phone: 610-849-1710
Email: [email protected]

SOURCE Tyber Medical


These press releases may also interest you

at 09:48
The global orthopedic device market  size is estimated to grow by USD 13.91 bn from 2024-2028, according to Technavio. The market is estimated to grow at a CAGR of almost 4.23%  during the forecast period. ...

at 09:45
It takes the average rare disease patient six years to get the right diagnosis. And even once they have a diagnosis, patients may face additional access challenges....

at 09:35
Pager, Inc., a leading digital healthcare enablement and care advocacy company serving 28 million members in the United States and Latin America, and AXA Partners Mexico (APM) today announced a strategic partnership that provides new capabilities to...

at 09:34
G Medical Innovations Holdings Ltd. (GMVD), a telehealth, medical device, and remote patient monitoring company, announced today a Partnership with Peter N Nielsen to Drive Health and Wellness Innovation. G Medical, a leading provider of innovative...

at 09:34
Ivy Rehab proudly announces its inclusion in Modern Healthcare's Best Places to Work in Healthcare 2024 list. This accolade highlights our commitment to fostering a positive and empowering work environment for our 5,000 team members. Ivy is the only...

at 09:30
Atara Biotherapeutics, Inc. , a leader in T-cell immunotherapy, leveraging its novel allogeneic Epstein-Barr virus (EBV) T-cell platform to develop transformative therapies for patients with cancer and autoimmune diseases, today announced that Atara...



News published on and distributed by: